There’s plenty of appeal to the Subaru Crosstrek for city and country buyers, but ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incor ...

Cytokinetics received U.S. FDA approval for MYQORZO on December 19, 2025. The approval was based on the positive results from the pivotal Phase 3 clinical trial, SEQUOIA-HCM, published in the New ...